[1] Mulshine JL, Sullivan DC. Clinical practice Lung cancer screening[J]. N Engl J Med, 2005, 352 (26):2714-2720. [2] Yahara J, Noguchi M, Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment[J]. BJU Int, 2003, 92(4): 379-383. [3] Ghosh P. The role of SPECT/CT in skeletal malignancies[J]. Semin Musculoskelet Radiol, 2014, 18(2): 175-193. [4] Gaeta CM, VercherConejero JL, Sher AC, et al. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers[J]. QJ Nucl Med Mol Imaging, 2013, 57(4): 352-366. [5] Chua S, Gnanasegaran G, Cook GJ. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases[J]. Semin Nucl Med, 2009, 39(6): 416-430. [6] Chang MC, Chen JH, Liang JA, et al. Metaanalysis: comparison of F18 fluorodeoxyglucose positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer[J]. Acad Radiol, 2012, 19(3): 349-357. [7] 张燕, 赵芬, 于金明. 18FFDG PETCT在结直肠癌综合治疗中的应用进展[J]. 国际肿瘤学杂志, 2012, 39(9): 699-702. |